Fate Therapeutics (FATE) is seeing an incredible amount of momentum. Since April 2020, the stock rocketed from a low of $19.92 to $35.23, as it moves progresses with cellular immunotherapies for cancer and immune disorders. Just days ago, Fate Therapeutics announced the U.S. FDA cleared its investigational new drug (IND) application for FT538, the first … Continue reading “Fate Therapeutics Announces U.S. FDA Clearance”
